Literature DB >> 18019081

Clinical case report: treatment of a central retinal vein occlusion with hyperbaric oxygen.

J K Wright1, B Franklin, E Zant.   

Abstract

A case of retinal central vein occlusion (CRVO) in a 43-year-old man is presented in which hyperbaric oxygen (HBO2) was used as the only treatment method. CRVO is a relatively common cause of visual loss, with hypertension, diabetes, glaucoma and hypercoagulable conditions identified as risk factors. The patient in this report had none of these risk factors and declined treatments other than hyperbaric oxygen. HBO2 was effective in sustaining the ischemic retina and controlling retinal edema until the retina revascularized and vision stabilized. The initial visual acuity in the left eye was 20/200 (corrected), and after two hyperbaric treatments it was 20/30 (corrected). Following three months of HBO2 treatments the vision stabilized to 20/20 (corrected) in the affected eye. Treatment considerations in using HBO2 as adjunctive therapy for CRVO are early institution of treatment, and continuation of HBO2 until the retinal edema has resolved and vision has stabilized.

Entities:  

Mesh:

Year:  2007        PMID: 18019081

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  11 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model.

Authors:  Wenbo Zhang; Harumasa Yokota; Zhimin Xu; Subhadra P Narayanan; Lauren Yancey; Akitoshi Yoshida; Dennis M Marcus; Robert W Caldwell; Ruth B Caldwell; Steven E Brooks
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-11       Impact factor: 4.799

3.  Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion.

Authors:  Yoav Y Pikkel; Adi Sharabi-Nov; Itzchak Beiran; Joseph Pikkel
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

Review 4.  Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Kristina Lindsley; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2014-05-01

Review 5.  Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy.

Authors:  David J Ramsey; G B Arden
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

6.  Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.

Authors:  Hua Liu; Wenbo Zhang; Zhimin Xu; Robert W Caldwell; Ruth B Caldwell; Steven E Brooks
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

7.  Hyperbaric oxygen treatment of central retinal vein occlusion with cilioretinal artery occlusion secondary to hormonal treatment: Case report and review.

Authors:  Asma Khallouli; Khaled Khelifi; Rahma Saidane; Racem Choura; Afef Maalej; Raja Ben Sassi
Journal:  Diving Hyperb Med       Date:  2020-12-20       Impact factor: 0.887

8.  The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions.

Authors:  Biljana Ivanovska Adjievska; Salih Boskurt; Nikola Orovcanec; Vesna Dimovska-Jordanova
Journal:  Clin Ophthalmol       Date:  2017-06-21

9.  The efficacy of hyperbaric oxygen therapy in the treatment of central retinal artery occlusion.

Authors:  Andreia Soares; Nuno L Gomes; Luís Mendonça; Carla Ferreira
Journal:  BMJ Case Rep       Date:  2017-05-12

10.  Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome.

Authors:  Joseph Pikkel; Otzem Chassid; Yumna Busool; Ward Srour; Adi Sharabi-Nov; Itzchak Beiran
Journal:  J Ophthalmol       Date:  2013-12-29       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.